Our website uses cookies which are small bits of data stored as text files on your device. We use these cookies as described in our cookie policy. You can disable or change your cookie settings at any time but parts of our site will not function correctly without them.

IncyteCARES is a program for residents of the United States and Puerto Rico.

Four Financial Assistance
Options for Your Patients

IncyteCARES: A Patient Assistance and Support Program IncyteCARES: A Patient Assistance and Support Program IncyteCARES: A Patient Assistance and Support Program

Enroll your eligible patients now.

They may qualify for the Copay/Coinsurance Program or other assistance options.*

*Terms and conditions apply. Terms of this program may change at any time.

copay card

FOR ELIGIBLE PATIENTS WITH COMMERCIAL OR PRIVATE PRESCRIPTION INSURANCE
IncyteCARES COPAY/COINSURANCE PROGRAM

Eligible patients can receive their medication for as little as $0 per month, subject to monthly and annual limits

Image of Patient Copay/Coinsurance Assistance Card

To qualify, patients must:

  • Have commercial or private prescription drug coverage. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible. Patients without prescription drug coverage are also not eligible
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for an Incyte medication for an FDA-approved use

Amount of savings for the purchase of Jakafi will not exceed $11,977 per month and $25,000 per year. Uninsured, cash-paying patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, and TRICARE or any state medical or pharmaceutical assistance program. Valid prescription for Jakafi for an FDA-approved indication is required. Please see complete Terms and Conditions or call IncyteCARES. Update effective as of September 30, 2019.

HOW TO ENROLL YOUR PATIENTS

Option 1: Enroll your patient in IncyteCARES.

We’ll do the rest. As part of our introductory call, we inform all newly enrolled patients about the Copay/Coinsurance Program and help eligible patients to apply for it.

Option 2: Complete an application at IncyteCAREScopay.com.

Once you submit the application, a patient membership number is immediately issued, and you or the specialty pharmacist can activate the patient’s program card right away at the same website. Your patient does not need to enroll in IncyteCARES to access the Copay/Coinsurance Program, if eligible.

For more information, call IncyteCARES at 1-855-452-5234, Monday through Friday, 8 am–8 pm ET.

Graphic representation of 2 people

FOR ELIGIBLE PATIENTS WHO ARE UNINSURED OR UNDERINSURED FOR JAKAFI® (ruxolitinib)
IncyteCARES PATIENT ASSISTANCE PROGRAM

Eligible patients can receive Jakafi free of charge

The IncyteCARES Patient Assistance Program (PAP) helps eligible patients who do not have prescription drug insurance or who have an insurance plan that will not cover their treatment with Jakafi.

To qualify, patients must:

  • Be confirmed as eligible for and enrolled in IncyteCARES
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for an Incyte medication for an FDA-approved use
  • Meet certain household size and annual income criteria, including earning less than $125,000 per year or less than 600% of the Federal Poverty Level (whichever amount is higher)
  • Patients with prescription coverage through government programs—including Medicare Part D, Medicare Advantage, Medicaid, TRICARE—or by a healthcare exchange plan are not eligible

HOW TO ENROLL YOUR PATIENTS

First, you must enroll your patient in IncyteCARES.

You can provide their required income information on the IncyteCARES enrollment form to start the process. Or we can explain the program and gather their income information during the introductory call we make to all patients newly enrolled in IncyteCARES.

Within 2 business days, patients are notified of "conditional approval," which allows them to receive free medication for 90 days. Full approval is only granted once income information is submitted and confirmed.

Terms and conditions apply. Terms of this program may change at any time.

Calendar

FOR PATIENTS WHOSE INSURANCE COVERAGE APPROVAL IS DELAYED
IncyteCARES TEMPORARY ACCESS PROGRAM

Eligible patients receive a free short-term supply of Jakafi§

If a patient’s prescription drug insurer requires more than a 3-day wait for determining coverage approval, we may be able to provide a free 30-day supply of the prescribed Incyte medication in the meantime. No purchase contingencies or other obligations apply.

To qualify, the patient must:

  • Be confirmed as eligible for and enrolled in IncyteCARES
  • Have commercial or private prescription drug coverage or a healthcare exchange plan. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible. Patients without prescription drug coverage are also not eligible
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for an Incyte medication for an FDA-approved use
  • Provide proof of the coverage delay. This may be a notice you or your patient receive from the insurance company

TO LEARN MORE

Call IncyteCARES at 1-855-452-5234, Monday through Friday, 8 am–8 pm ET.

§Terms and conditions apply. Terms of this program may change at any time.

hand with heart

FOR PATIENTS COVERED BY ANY TYPE OF INSURANCE OR WITHOUT INSURANCE
INFORMATION ABOUT NONPROFIT OR OTHER SUPPORT ORGANIZATIONS

Patients may be eligible for help with medication, treatment-related travel, and other costs

If your patients do not qualify for our IncyteCARES Copay/Coinsurance Program or Patient Assistance Program, we may be able to provide information about other organizations or independent foundations that may offer help. Some assist with medication costs, transportation or lodging expenses related to treatment, or counseling services, offered at reduced or no cost. Eligibility and availability of these assistance programs are determined by the individual organizations.

TO LEARN MORE

Call IncyteCARES at 1-855-452-5234, Monday through Friday, 8 am–8 pm ET.

"It was a huge relief to have the copay help.
I couldn’t believe how easy it was."

– Sue W.

INDICATIONS AND USAGE

Jakafi is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.

Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.

Jakafi is also indicated for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.

IMPORTANT SAFETY INFORMATION

  • Treatment with Jakafi® (ruxolitinib) can cause thrombocytopenia, anemia and neutropenia, which are each dose‐related effects. Perform a pre‐treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated
  • Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary
  • Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi
  • Severe neutropenia (ANC <0.5 x 109/L) was generally reversible by withholding Jakafi until recovery
  • Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly. Use active surveillance and prophylactic antibiotics according to clinical guidelines.
  • Tuberculosis (TB) infection has been reported. Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly. Prior to initiating Jakafi, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB. Continuation of Jakafi during treatment of active TB should be based on the overall risk-benefit determination
  • Progressive multifocal leukoencephalopathy (PML) has occurred with Jakafi treatment. If PML is suspected, stop Jakafi and evaluate
  • Advise patients about early signs and symptoms of herpes zoster and to seek early treatment
  • Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections. Monitor and treat patients with chronic HBV infection according to clinical guidelines
  • When discontinuing Jakafi, myeloproliferative neoplasm-related symptoms may return within one week. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, DIC, or multi-organ failure. If any of these occur after discontinuation or while tapering Jakafi, evaluate and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi without consulting their physician. When discontinuing or interrupting Jakafi for reasons other than thrombocytopenia or neutropenia, consider gradual tapering rather than abrupt discontinuation
  • Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations
  • Treatment with Jakafi has been associated with increases in total cholesterol, low-density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8-12 weeks after initiating Jakafi. Monitor and treat according to clinical guidelines for the management of hyperlipidemia
  • In myelofibrosis and polycythemia vera, the most common nonhematologic adverse reactions (incidence ≥15%) were bruising, dizziness, headache, and diarrhea. In acute graft-versus-host disease, the most common nonhematologic adverse reactions (incidence >50%) were infections and edema
  • Dose modifications may be required when administering Jakafi with strong CYP3A4 inhibitors or fluconazole or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy
  • Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking Jakafi should not breastfeed during treatment and for 2 weeks after the final dose